IDRA Idera Pharmaceuticals Inc.

3.98
-2.62  -40%
Previous Close 6.6
Open 5.88
Price To Book 1.45
Market Cap 108182115
Shares 27,181,436
Volume 1,008,921
Short Ratio
Av. Daily Volume 210,169

SEC filingsSee all SEC filings

  1. 8-K - Current report 181234550
  2. 8-K - Current report 181201498
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181201488
  4. 8-K - Current report 181163817
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163216

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data December 14, 2018 noted 11/34 PRs including 2 CRs.
Tilsotolimod + ipilimumab - ILLUMINATE 204
Cancer - melanoma
Development suspended - September 2016.
IMO-8400
Waldenström’s Macroglobulinemia
Development suspended - September 2016.
IMO-8400
Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 data released June 12, 2018 - primary endpoint not met.
IMO-8400
Dermatomyositis
Phase 1 trial is ongoing.
Tilsotolimod and pembrolizumab
Solid tumors
Phase 1b trial is ongoing. Data due 2019.
Tilsotolimod - ILLUMINATE 101
Solid tumors

Latest News

  1. Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
  2. Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018
  3. United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries — Future Expectations, Projections Moving into 2018
  4. The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
  5. How Many Idera Pharmaceuticals Inc (NASDAQ:IDRA) Shares Do Institutions Own?
  6. Idera Pharmaceuticals (IDRA) Reports Q3 Loss, Lags Revenue Estimates
  7. Idera: 3Q Earnings Snapshot
  8. Idera Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  9. Idera Pharmaceuticals Presents Data from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment at the 2018 European Society for Medical Oncology (ESMO) Congress
  10. vTv Therapeutics (VTVT) Looks Good: Stock Adds 5.8% in Session
  11. What does Idera Pharmaceuticals Inc’s (NASDAQ:IDRA) Balance Sheet Tell Us About Its Future?
  12. Idera Pharmaceuticals Announces Appointment of Howard Pien to its Board of Directors
  13. These 3 Stocks Crushed It This Week: Are They Buys Now?
  14. 3 Beaten-Down Biotech Stocks: Can They Recover?
  15. Today’s Research Reports on Stocks to Watch: Portola Pharmaceuticals and Idera Pharmaceuticals

SEC Filings

  1. 8-K - Current report 181234550
  2. 8-K - Current report 181201498
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181201488
  4. 8-K - Current report 181163817
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163216
  6. 8-K - Current report 181155564
  7. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181080089
  8. 8-K - Current report 181077037
  9. 8-K - Current report 181068964
  10. SC 13G - Statement of acquisition of beneficial ownership by individuals 181052792